Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) Return on Equity: 2022-2025

Historic Return on Equity for Axsome Therapeutics (AXSM) over the last 3 years, with Sep 2025 value amounting to -3.13%.

  • Axsome Therapeutics' Return on Equity rose 5.00% to -3.13% in Q3 2025 from the same period last year, while for Sep 2025 it was -3.13%, marking a year-over-year increase of 5.00%. This contributed to the annual value of -2.32% for FY2024, which is 72.00% down from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Return on Equity is -3.13%, which was up 20.03% from -3.91% recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Return on Equity high stood at -0.74% for Q3 2023, and its period low was -5.05% during Q1 2025.
  • Over the past 3 years, Axsome Therapeutics' median Return on Equity value was -2.50% (recorded in 2024), while the average stood at -2.50%.
  • Per our database at Business Quant, Axsome Therapeutics' Return on Equity spiked by 36bps in 2023 and then slumped by 328bps in 2025.
  • Over the past 4 years, Axsome Therapeutics' Return on Equity (Quarterly) stood at -1.40% in 2022, then soared by 36bps to -1.04% in 2023, then slumped by 279bps to -3.83% in 2024, then rose by 5bps to -3.13% in 2025.
  • Its Return on Equity was -3.13% in Q3 2025, compared to -3.91% in Q2 2025 and -5.05% in Q1 2025.